Trial record 4 of 483 for:
"Fibromyalgia"
Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia
This study has been completed.
Sponsor:
Institut Nacional d'Educacio Fisica de Catalunya
Information provided by:
Institut Nacional d'Educacio Fisica de Catalunya
ClinicalTrials.gov Identifier:
NCT00650715
First received: March 31, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study was to investigate the acute and chronic effect of whole-body vibration exercise on serum insulin-like growth factor-1 levels in women with fibromyalgia (FM). It was hypothesized that women with FM would exhibit an increase in IGF-1 following both acute and chronic WBV. Twenty-four women with FM were randomized into two groups: Vibration Group (VG) and Control Group (CG). The VG underwent a protocol with WBV exercise twice a week for a total of six weeks, whereas the CG performed the same protocol without vibratory stimulus. Both groups continued with their usual pharmacological treatment. Serum IGF-1 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA). To test the effect of chronic WBV, serum IGF-1 measurements were taken at baseline and at weeks 1,3, and 6 of intervention. To test the effect of acute WBV, within week 1, serum IGF-1 measurements were taken before and immediately following a session of WBV.
| Condition | Intervention |
|---|---|
|
Fibromyalgia Hormonal Responses to Exercise in Patients With Fibromyalgia. |
Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands Device: Placebo Whole-body vibration exercise |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia |
Resource links provided by NLM:
Further study details as provided by Institut Nacional d'Educacio Fisica de Catalunya:
Primary Outcome Measures:
- Serum IGF-1 levels [ Time Frame: Baseline, Week 1, Week 3, Week 6 ] [ Designated as safety issue: Yes ]
| Enrollment: | 24 |
| Study Start Date: | December 2004 |
| Study Completion Date: | January 2005 |
| Primary Completion Date: | January 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: VG
Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
|
Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
|
|
Placebo Comparator: CG
The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
|
Device: Placebo Whole-body vibration exercise
Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
|
Eligibility| Ages Eligible for Study: | 35 Years to 69 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria for at least three years.
Exclusion Criteria:
- Orthopedic limitation, or cardiovascular, pulmonary, or metabolic disease that would preclude exercise.
- Participation in any other study.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00650715
Please refer to this study by its ClinicalTrials.gov identifier: NCT00650715
Locations
| Spain | |
| Institut Nacional d'Educación Física de Catalunya | |
| Barcelona, Spain, 08038 | |
Sponsors and Collaborators
Institut Nacional d'Educacio Fisica de Catalunya
Investigators
| Principal Investigator: | Eduard Alentorn-Geli, MD | INEFC |
More Information
No publications provided
| Responsible Party: | Eduard Alentorn-Geli, MD, INEFC |
| ClinicalTrials.gov Identifier: | NCT00650715 History of Changes |
| Other Study ID Numbers: | WBVIGF1FM |
| Study First Received: | March 31, 2008 |
| Last Updated: | March 31, 2008 |
| Health Authority: | Spain: Ethics Committee |
Keywords provided by Institut Nacional d'Educacio Fisica de Catalunya:
|
Fibromyalgia Whole-Body vibration Exercise IGF-1 |
Additional relevant MeSH terms:
|
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Nervous System Diseases Neuromuscular Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on March 01, 2015